Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Piperidines"" wg kryterium: Temat


Tytuł:
Balancing neuronal circuits.
Autorzy:
Blumenstock S; Molecular Neurodegeneration Group, Max Planck Institute for Biological Intelligence, i.f., Martinsried, Germany.; Department of Molecules-Signaling-Development, Max Planck Institute for Biological Intelligence, i.f., Martinsried, Germany.; Department of Neurobiology, Center for Neural Circuits and Behavior, Department of Neurosciences, University of California, San Diego, CA, USA.
Dudanova I; Molecular Neurodegeneration Group, Max Planck Institute for Biological Intelligence, i.f., Martinsried, Germany.; Department of Molecules-Signaling-Development, Max Planck Institute for Biological Intelligence, i.f., Martinsried, Germany.; Center for Anatomy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Sep 23; Vol. 377 (6613), pp. 1383-1384. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Dioxoles*/pharmacology
Dioxoles*/therapeutic use
Huntington Disease*/embryology
Huntington Disease*/genetics
Huntington Disease*/prevention & control
Nerve Net*/abnormalities
Nerve Net*/pathology
Piperidines*/pharmacology
Piperidines*/therapeutic use
Synapses*/drug effects
Synapses*/pathology
Aging ; Animals ; Mice ; Mice, Transgenic ; Neurons/drug effects ; Neurons/pathology ; Neurons/physiology
Czasopismo naukowe
Tytuł:
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Autorzy:
Dong R; Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China.
Yan Y; Translational Medicine Research Center, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 31006, People's Republic of China.
Zeng X; Department of Critical Care Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 31006, People's Republic of China.
Lin N; Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China.; Translational Medicine Research Center, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 31006, People's Republic of China.
Tan B; Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People's Republic of China.
Pokaż więcej
Źródło:
Drug design, development and therapy [Drug Des Devel Ther] 2022 Sep 20; Vol. 16, pp. 3225-3239. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Adenine*/analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors
Cardiotoxicity*/etiology
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Piperidines*/adverse effects
Piperidines*/therapeutic use
Protein Kinase Inhibitors*/adverse effects
Protein Kinase Inhibitors*/therapeutic use
Humans
Czasopismo naukowe
Tytuł:
Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Autorzy:
Bai JF; Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland.
Majjigapu SR; Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland.
Sordat B; Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland.
Poty S; Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland.
Vogel P; Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Institute of Technology (EPFL), 1015, Lausanne, Switzerland.
Elías-Rodríguez P; Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain.
Moreno-Vargas AJ; Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain.
Carmona AT; Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain.
Caffa I; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Ghanem M; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy.
Khalifa A; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Monacelli F; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Cea M; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
Robina I; Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Sevilla, 41012, Spain.
Gajate C; Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Mollinedo F; Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Bellotti A; Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland.
Nahimana A; Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland.
Duchosal M; Central Laboratory of Hematology, Medical Laboratory and Pathology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland; Service of Hematology, Oncology Department, Lausanne University Hospital, 1011, Lausanne, Switzerland.
Nencioni A; Department of Internal Medicine and Medical Specialties, University of Genoa, 16132, Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2022 Sep 05; Vol. 239, pp. 114504. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Journal Article
MeSH Terms:
Acrylamides*/chemistry
Acrylamides*/pharmacology
Antineoplastic Agents*/pharmacology
Carcinoma, Pancreatic Ductal*/drug therapy
Pancreatic Neoplasms*/drug therapy
Piperidines*/chemistry
Piperidines*/pharmacology
Cytokines ; Humans
SCR Disease Name:
Pancreatic Carcinoma
Czasopismo naukowe
Tytuł:
Mechanistic insights on novel small molecule allosteric activators of cGMP-dependent protein kinase PKG1α.
Autorzy:
Tawa P; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Zhang L; Biologics AR&D Immunoassay Group, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Metwally E; Computational & Structural Chemistry, Merck & Co, Inc, South San Francisco, California, USA.
Hou Y; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
McCoy MA; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Seganish WM; Discovery Chemistry, Merck & Co, Inc, South San Francisco, California, USA.
Zhang R; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Frank E; Quantitative Biosciences, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Sheth P; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Hanisak J; Discovery Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Sondey C; Quantitative Biosciences, Merck & Co, Inc, Boston, Massachusetts, USA.
Bauman D; Discovery Biology, Merck & Co, Inc, Kenilworth, New Jersey, USA.
Soriano A; Mass Spectrometry & Biophysics, Computational & Structural Chemistry, Merck & Co, Inc, Kenilworth, New Jersey, USA. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2022 Sep; Vol. 298 (9), pp. 102284. Date of Electronic Publication: 2022 Jul 19.
Typ publikacji:
Journal Article
MeSH Terms:
Cardiovascular Diseases*/drug therapy
Cardiovascular Diseases*/enzymology
Cyclic GMP*/metabolism
Cyclic GMP-Dependent Protein Kinase Type I*/metabolism
Piperidines*/pharmacology
Piperidines*/therapeutic use
Adenosine Triphosphate/metabolism ; Allosteric Regulation/drug effects ; Allosteric Site/drug effects ; Humans ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology
Czasopismo naukowe
Tytuł:
Tofacitinib for sarcoidosis, a new potential treatment.
Autorzy:
Xu Q; The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Huang ZS; The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Liu QP; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Wei JC; Department of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.; Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan.; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Pokaż więcej
Źródło:
International journal of rheumatic diseases [Int J Rheum Dis] 2022 Nov; Vol. 25 (11), pp. 1217-1219.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Piperidines*
Sarcoidosis*
Humans ; Pyrimidines ; Pyrroles ; Protein Kinase Inhibitors
Opinia redakcyjna
Tytuł:
Influence of genetic variants on remifentanil sensitivity in Chinese women.
Autorzy:
Niu H; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhao S; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Wang Y; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Huang S; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhou R; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Wu Z; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Song W; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen X; Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Nov; Vol. 47 (11), pp. 1858-1866. Date of Electronic Publication: 2022 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Piperidines*/pharmacology
Respiratory Insufficiency*
Humans ; Female ; Remifentanil ; Analgesics, Opioid/pharmacology ; Pain ; China
Czasopismo naukowe
Tytuł:
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Autorzy:
Fisch SC; University of California Davis School of Medicine, Sacramento, CA, USA.
Tuscano JM; Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Bone Marrow Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.
Qi L; Department of Public Health Sciences, Division of Biostatistics, University of California Davis, Davis, CA, USA.
Jonas BA; Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Bone Marrow Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA. Electronic address: .
Pokaż więcej
Źródło:
Leukemia research [Leuk Res] 2022 Nov; Vol. 122, pp. 106947. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Clinical Trial, Phase I; Letter
MeSH Terms:
Piperidines*
Adenine*
Humans ; Lenalidomide ; Chromosome Deletion
Raport
Tytuł:
TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).
Autorzy:
Kleinrensink NJ; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.; Radiology, UMC Utrecht, Utrecht, The Netherlands.
Perton FT; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands .
Pouw JN; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Vincken NLA; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Hartgring SAY; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jansen MP; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Arbabi S; Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands.; Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands.
Foppen W; Radiology, UMC Utrecht, Utrecht, The Netherlands.
de Jong PA; Radiology, UMC Utrecht, Utrecht, The Netherlands.
Tekstra J; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Leijten EFA; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Spierings J; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Lafeber FPJG; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Welsing PMJ; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Heijstek MW; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Corporate Authors:
TOFA-PREDICT author group
Źródło:
BMJ open [BMJ Open] 2022 Oct 10; Vol. 12 (10), pp. e064338. Date of Electronic Publication: 2022 Oct 10.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antirheumatic Agents*/therapeutic use
Arthritis, Psoriatic*/drug therapy
Piperidines*/therapeutic use
Pyrimidines*/therapeutic use
Biomarkers ; Clinical Trials, Phase III as Topic ; Etanercept/therapeutic use ; Furans ; Humans ; Immunologic Factors/therapeutic use ; Methotrexate/therapeutic use ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł:
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia.
Autorzy:
Castillo JJ; Bing Center for Waldenström Macroglobulinöemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Tam CS; Peter MacCallum Cancer Centre, Melbourne, Australia.
Garcia-Sanz R; Hospital Universitario de Salamanca, Salamanca, Spain.
Opat S; Monash Health, Monash Uniöversity, Clayton, Australia.
D'Sa S; Centre for Waldenström's Macroglobulinemia and Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom.
Jurczak W; Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland.
Lee HP; Flinders Medical Centre, Adelaide, Australia.
Cull G; Sir Charles Gairdner Hospital, University of Western Australia Perth, Perth, Australia.
Owen RG; St. James University Hospital, Leeds, United Kingdom.
Marlton P; Princess Alexandra Hospital, University of Queensland Brisbane, Brisbane, Australia.
Wahlin BE; Karolinska Universitetssjukhuset and Karolinska Institutet, Stockholm, Sweden.
Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Siddiqi T; City Of Hope National Medical Center, Duarte, USA.
Buske C; CCC UIm - Universitätsklinikum Ulm, Ulm, Germany.
Leblond V; Sorbonne University, Pitié Salpêtrière Hospital, Paris, France.
Chan WY; BeiGene USA, Inc., San Mateo, USA.
Schneider J; BeiGene USA, Inc., San Mateo, USA.
Cohen A; BeiGene USA, Inc., San Mateo, USA.
Dimopoulos M; National and Kapodistrian University of Athens, Athens, Greece.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Oct; Vol. 22 Suppl 2, pp. S385.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Adenine*/analogs & derivatives
Piperidines*/adverse effects
Pyrazoles*/adverse effects
Pyrimidines*/adverse effects
Waldenstrom Macroglobulinemia*/drug therapy
Waldenstrom Macroglobulinemia*/genetics
Aged ; Atrial Fibrillation/chemically induced ; Follow-Up Studies ; Humans ; Hypertension/chemically induced ; Lymphoma, B-Cell ; Myeloid Differentiation Factor 88/genetics ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł:
Case report: Refractory intestinal Behçet's syndrome successfully treated with tofacitinib: A report of four cases.
Autorzy:
Zhao N; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Tang Y; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Wang S; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Cui L; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Sun X; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Wang Z; Department of Gastroenterology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Liu Y; Department of Rheumatology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Sep 15; Vol. 13, pp. 981502. Date of Electronic Publication: 2022 Sep 15 (Print Publication: 2022).
Typ publikacji:
Case Reports; Journal Article; Review
MeSH Terms:
Behcet Syndrome*/drug therapy
Janus Kinase Inhibitors*/therapeutic use
Piperidines*/therapeutic use
Pyrimidines*/therapeutic use
Antibodies, Monoclonal/therapeutic use ; Biological Factors/therapeutic use ; COVID-19/epidemiology ; Humans ; Immunosuppressive Agents/therapeutic use ; Intestines/pathology ; Janus Kinases ; Prospective Studies ; Tumor Necrosis Factor Inhibitors ; Ulcer/drug therapy
Czasopismo naukowe
Tytuł:
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2.
Autorzy:
Meanwell NA; Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Post Office Box 4000, Princeton, New Jersey 08543, United States.
Loiseleur O; Syngenta Crop Protection Research, Schaffhauserstrasse, CH-4332 Stein, Switzerland.
Pokaż więcej
Źródło:
Journal of agricultural and food chemistry [J Agric Food Chem] 2022 Sep 14; Vol. 70 (36), pp. 10972-11004. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Piperidines*
Pyrrolidines*
Drug Design ; Piperazine
Czasopismo naukowe
Tytuł:
Amelioration of injury-induced tissue acidosis by a nonsteroidal analgesic attenuates antinociceptive effects of the pH-dependent opioid agonist NFEPP.
Autorzy:
Celik MÖ; Department of Experimental Anesthesiology (CBF), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. .
Negrete R; Department of Experimental Anesthesiology (CBF), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.
Di Rosso R; Department of Experimental Anesthesiology (CBF), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.
Machelska H; Department of Experimental Anesthesiology (CBF), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.
Stein C; Department of Experimental Anesthesiology (CBF), Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Sep 07; Vol. 12 (1), pp. 15172. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't
MeSH Terms:
Acidosis*/chemically induced
Acidosis*/drug therapy
Analgesics, Opioid*/adverse effects
Piperidines*/pharmacology
Analgesics/pharmacology ; Animals ; Hydrogen-Ion Concentration ; Inflammation/chemically induced ; Inflammation/drug therapy ; Rats ; Receptors, Opioid/metabolism
Czasopismo naukowe
Tytuł:
Improvement of urethral dysfunction by 5-HT 1A  receptor agonist NLX-112 in diabetic rats.
Autorzy:
Li M; Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Chen X; Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Cao N; Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Lv R; Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Gu B; Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Pokaż więcej
Źródło:
Neurourology and urodynamics [Neurourol Urodyn] 2022 Sep; Vol. 41 (7), pp. 1528-1538. Date of Electronic Publication: 2022 Jul 23.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Experimental*/chemically induced
Diabetes Mellitus, Experimental*/complications
Diabetes Mellitus, Type 1*/chemically induced
Diabetes Mellitus, Type 1*/complications
Piperidines*/pharmacology
Pyridines*/pharmacology
Serotonin 5-HT1 Receptor Antagonists*/pharmacology
Urethra*/physiopathology
Animals ; Female ; Maleates ; Rats ; Rats, Sprague-Dawley ; Receptor, Serotonin, 5-HT1A ; Serotonin ; Streptozocin
Czasopismo naukowe
Tytuł:
Pharmacological inhibition of DKK1 promotes spine fusion in an ovariectomized rat model.
Autorzy:
Li Z; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA.
Xing X; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA.
Gomez-Salazar MA; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA.
Xu M; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA.
Negri S; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA; Department of Orthopaedics and Traumatology, University of Verona, Verona 37129, Italy.
Xu J; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA.
James AW; Department of Pathology, Johns Hopkins University, Baltimore, MD 21205,USA. Electronic address: .
Pokaż więcej
Źródło:
Bone [Bone] 2022 Sep; Vol. 162, pp. 116456. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't
MeSH Terms:
Mesenchymal Stem Cells*
Naphthalenes*/pharmacology
Osteoporosis*/drug therapy
Piperidines*/pharmacology
Pyrimidines*/pharmacology
Animals ; Cell Differentiation ; Female ; Humans ; Intercellular Signaling Peptides and Proteins ; Osteogenesis ; Ovariectomy ; Rats ; Wnt Signaling Pathway
Czasopismo naukowe
Tytuł:
The attenuation effect of low piperine Piper nigrum extract on doxorubicin-induced toxicity of blood chemical and immunological properties in mammary tumour rats.
Autorzy:
Saetang J; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.; Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.; EZ-Mol-Design Laboratory, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Tedasen A; Department of Medical Technology, School of Allied Health Sciences and Public Health, Walailak University, Thai Buri, Thailand.
Sangkhathat S; Department of Surgery, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Sangkaew N; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Dokduang S; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Prompat N; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Taraporn S; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Graidist P; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Pokaż więcej
Źródło:
Pharmaceutical biology [Pharm Biol] 2022 Dec; Vol. 60 (1), pp. 96-107.
Typ publikacji:
Journal Article
MeSH Terms:
Alkaloids/*pharmacology
Benzodioxoles/*pharmacology
Doxorubicin/*toxicity
Piper nigrum/*chemistry
Piperidines/*pharmacology
Plant Extracts/*pharmacology
Polyunsaturated Alkamides/*pharmacology
Alkaloids/administration & dosage ; Alkaloids/isolation & purification ; Animals ; Antibiotics, Antineoplastic/toxicity ; Antioxidants/administration & dosage ; Antioxidants/isolation & purification ; Antioxidants/pharmacology ; Benzodioxoles/administration & dosage ; Benzodioxoles/isolation & purification ; Dose-Response Relationship, Drug ; Female ; Mammary Neoplasms, Experimental/drug therapy ; Piperidines/administration & dosage ; Piperidines/isolation & purification ; Plant Extracts/administration & dosage ; Plant Extracts/chemistry ; Polyunsaturated Alkamides/administration & dosage ; Polyunsaturated Alkamides/isolation & purification ; Rats ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł:
Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors.
Autorzy:
Zhao L; Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Yang Q; Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Tang Y; Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
You Q; Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Guo X; Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 462-471.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Design*
Kv1.5 Potassium Channel/*antagonists & inhibitors
Piperidines/*pharmacology
Potassium Channel Blockers/*pharmacology
Dose-Response Relationship, Drug ; Humans ; Kv1.5 Potassium Channel/metabolism ; Molecular Structure ; Piperidines/chemical synthesis ; Piperidines/chemistry ; Potassium Channel Blockers/chemical synthesis ; Potassium Channel Blockers/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł:
High-resolution accurate mass approach to characterization of SCO-267 metabolites using liquid chromatography hybrid quadrupole Orbitrap mass spectrometry.
Autorzy:
Zhu Y; Department of Pharmacy, Xuzhou Central Hospital, Jiangsu Province, Xuzhou, China.
Wang T; Department of Pharmacy, Zhangjiagang Hospital of Traditional Chinese Medicine, Jiangsu Province, Zhangjiagang, China.
Zhao N; Department of Pharmacy, Zhangjiagang Hospital of Traditional Chinese Medicine, Jiangsu Province, Zhangjiagang, China.
Jiang W; Department of Pharmacy, Zhangjiagang Hospital of Traditional Chinese Medicine, Jiangsu Province, Zhangjiagang, China.
Pokaż więcej
Źródło:
Rapid communications in mass spectrometry : RCM [Rapid Commun Mass Spectrom] 2022 Jul 30; Vol. 36 (14), pp. e9325.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/metabolism
Piperidines*/chemistry
Piperidines*/pharmacokinetics
Pyridines*/chemistry
Pyridines*/pharmacokinetics
Tandem Mass Spectrometry*/methods
Animals ; Chromatography, High Pressure Liquid/methods ; Chromatography, Liquid/methods ; Cytochrome P-450 CYP2C8/metabolism ; Microsomes, Liver/metabolism ; Rats
Czasopismo naukowe
Tytuł:
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Autorzy:
Polavieja P; Eli Lilly and Company, Indianapolis, Indiana, USA. polavieja_.; Avenida de la Industria 30, 28108, Alcobendas, Madrid, Spain. polavieja_.
Belger M; Eli Lilly and Company, Indianapolis, Indiana, USA.
Venkata SK; Eli Lilly and Company, Indianapolis, Indiana, USA.
Wilhelm S; Eli Lilly and Company, Indianapolis, Indiana, USA.
Johansson E; Eli Lilly and Company, Indianapolis, Indiana, USA.
Pokaż więcej
Źródło:
The journal of headache and pain [J Headache Pain] 2022 Jul 06; Vol. 23 (1), pp. 76. Date of Electronic Publication: 2022 Jul 06.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Benzamides*/adverse effects
Benzamides*/therapeutic use
Migraine Disorders*/drug therapy
Piperidines*/adverse effects
Piperidines*/therapeutic use
Pyridines*/adverse effects
Pyridines*/therapeutic use
Pyrroles*/adverse effects
Pyrroles*/therapeutic use
Adult ; Double-Blind Method ; Female ; Humans ; Middle Aged ; Network Meta-Analysis ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
Autorzy:
van Berge Henegouwen JM; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
van der Wijngaart H; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Zeverijn LJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hoes LR; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Meertens M; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Labots M; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jul; Vol. 90 (1), pp. 97-104. Date of Electronic Publication: 2022 May 22.
Typ publikacji:
Case Reports; Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/pharmacokinetics
Azetidines*/adverse effects
Azetidines*/pharmacokinetics
Piperidines*/adverse effects
Piperidines*/pharmacokinetics
Skin Neoplasms*/drug therapy
Skin Neoplasms*/genetics
Thyroid Neoplasms*/drug therapy
Thyroid Neoplasms*/genetics
Vemurafenib*/adverse effects
Vemurafenib*/pharmacokinetics
Humans ; Proto-Oncogene Proteins B-raf/genetics
Czasopismo naukowe
Tytuł:
Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.
Autorzy:
Vincken NLA; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Welsing PMJ; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Silva-Cardoso SC; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Bekker CPJ; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Lopes AP; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Olde Nordkamp M; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Leijten EFA; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Radstake TRDJ; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Angiolilli C; Center for Translational Immunology, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
Experimental dermatology [Exp Dermatol] 2022 Jun; Vol. 31 (6), pp. 962-969. Date of Electronic Publication: 2022 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Interferon-gamma*/metabolism
Interleukin-12 Subunit p40*/antagonists & inhibitors
Interleukin-12 Subunit p40*/blood
Interleukin-12 Subunit p40*/metabolism
Janus Kinase Inhibitors*/pharmacology
Janus Kinase Inhibitors*/therapeutic use
Piperidines*/pharmacology
Piperidines*/therapeutic use
Psoriasis*/drug therapy
Pyrimidines*/pharmacology
Pyrimidines*/therapeutic use
Skin*/drug effects
Skin*/immunology
Arthritis, Psoriatic/drug therapy ; Dendritic Cells/immunology ; Humans ; Lipopolysaccharides/immunology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz